References and Notes

 

 

1.        The Physicians Committee for Responsible Medicine (Washington, D.C., www.pcrm.org), the Medical Research Modernization Committee (Cleveland, Ohio, www.mrmcmed.org) and Europeans for Medical Progress (London, U.K., www.curedisease.net) combined have over 10,000 physician and scientist members, most of whom are highly critical of animal experimentation.

2.             Barnard ND, Kaufman SR. Animal research is wasteful and misleading. Scientific American 1997; Feb: 80-82.

3.             Mukerjee M. Trends in animal research. Scientific American 1997; Feb: 86-93.

4.             www.curedisease.net/news/040903.shtml.

5.             Loeb JM, Hendee WR, Smith SJ, Schwartz R. Human vs. animal rights: In defense of animal research. Journal of the American Medical Association 1989; 262: 2716-2720.

6.             Botting JH, Morrison AD. Animal research is vital to medicine. Scientific American 1997; Feb: 83-85.

7.             Reines BP. On the locus of medical discovery. Journal of Medicine and Philosophy 1991; 116: 183-209.

8.             Reines BP. On the role of clinical anomaly in Harvey's discovery of the mechanism of the pulse. Perspectives in Biology and Medicine 1990; 34: 128-133.

9.             McQuarrie I. The Experiments of Nature and Other Essays from the Porter Lectures. Lawrence, Kansas, University of Kansas Press, 1944.

10.         Peller S. Quantitative Research in Human Biology and Medicine. Bristol, England, John Wright & Sons, 1967.

11.         Beeson PB. The growth of knowledge about a disease: hepatitis. American Journal of Medicine 1979; 67: 366-370.

12.         Good RA. Runestones in immunology. Journal of Immunology 1976; 117: 1413-1428.

13.         Good RA. Keystones. Journal of Clinical Investigation 1968; 47: 1466-1471. Beeson and Good have recently emphasized that they do not oppose animal experimentation, and that they consider it important to medical progress. However, their own articles speak for themselves.

14.         Greek CR, Greek JW. Sacred Cows and Golden Geese. New York, Continuum, 2000.

15.         Greek CR, Greek JW. Specious Science. New York, Continuum, 2002.

16.         Greek JS, Greek CR. What Will We Do If We Don't Experiment on Animals? Medical Research for the Twenty-First Century. Victoria, B.C., Trafford, 2004.

17.         Brecher R. The Consumers Union Report on Smoking and the Public Interest. Mount Vernon, Consumers Union, 1963.

18.         Doll R, Hill AB. The mortality of doctors in relation to their smoking habits: A preliminary report. British Medical Journal 1954; 1: 1451-1455.

19.         Northrup E. Men, mice, and smoking, in Science Looks at Smoking. New York, Coward-McCann, 1957, p 133.

20.         Enterline PE. Asbestos and cancer, in Gordis L (ed). Epidemiology & Health Risk Assessment. New York, Oxford University Press, 1988.

21.         Gardner MJ, Snee MP, Hall AJ, et al. Results of case-control study of leukaemia and lymphoma among young people near Sellafield nuclear plant in West Cumbria. British Medical Journal 1990; 300: 423-429.

22.         Wald ML. Pioneer in radiation sees risk even in small doses. New York Times Dec 8, 1994, p A1.

23.         Stewart A. Alternative sources of risk estimates for cancer effects of radiation. The Mount Sinai Journal of Medicine 1995; 62: 380-385.

24.         Gould JM, Sternglass EJ. Nuclear fallout, low birthweight, and immune deficiency. International Journal of Health Science 1994; 24: 311-335.

25.         Bross ID. Fifty Years of Folly and Fraud "In the Name of Science." Buffalo, Biomedical Metatechnology, 1994.

26.         Ainley CC, Senapati A, Brown IM, et al. Is alcohol hepatotoxic in the baboon? Journal of Hepatology 1988; 7: 85-92.

27.         Dowling HF. Fighting Infection. Cambridge, Massachusetts, Harvard University Press, 1977.

28.         Parish HJ. Victory with Vaccines. Edinburgh and London, E&S Livingstone Ltd., 1968.

29.         Paul JR. History of Poliomyelitis. New Haven, Yale University Press, 1971.

30.         Sabin AB. Statement of Albert B. Sabin, M.D. Hearing before the Subcommittee on Hospitals and Health Care of the Committee on Veterans' Affairs of the House of Representatives, April 26, 1984, serial no. 98-48.

31.         Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissue. Science 1949; 109: 85-86.

32.         Domingo RT, Fries C, Sawyer P, Wesolowski S. Peripheral arterial reconstruction. Transplantation of autologous veins. Transactions of the American Society of Artificial Internal Organs 1963; 9: 305-316.

33.         Hume D. Experiences with renal homotransplantation in the human subject. Journal of Clinical Investigation 1955; 34: 327-381.

34.         American Medical Association Council on Scientific Affairs. Animals in research. Journal of the American Medical Association 1989; 261: 3602-3606.

35.         Bailar JC III, Gornik HL. Cancer undefeated. New England Journal of Medicine 1997; 336: 1569-1574.

36.         Beardsley T. A war not won. Scientific American 1994: 270(1); 130-138.

37.         Jamal A, Thomas A, Murray T, Thun M. Cancer Statistics, 2002. CA Cancer Journal for Clinicians 2002; 52: 23-47.

38.         US General Accounting Office. Cancer Patient Survival: What Progress Has Been Made? Washington, DC, General Accounting Office, 1987.

39.         Bailar JC, Smith EM. Progress against cancer? New England Journal of Medicine 1986; 314: 1226-32.

40.         Dulbecco R. A turning point in cancer research: Sequencing the human genome. Science 1986; 231: 1055-1056.

41.         Leavitt J. The case for understanding the molecular nature of cancer: Some recent findings and their implications. Medical News Sept 9, 1985.

42.         Bross I. Crimes of Official Science. Buffalo, Biomedical Metatechnology, 1987.

43.         Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-467.

44.         Lab Animal June 2001; 30 (6): 13.

45.         Leaf C. Why we're losing the war on cancer – and how to win it. Fortune Magazine March 22, 2004.

46.         Gardner MB, Luciw PA. Animal Models of AIDS. FASEB Journal 1989; 3: 2593-2606.

47.         O’Niel, SP et al. Progressive infection in a subset of HIV-1 positive chimpanzees. The Journal of Infections Diseases 2000; 182 (4): 1051-1062.

48.         Novembre FJ et al. Rapid CD4+ T-cell loss induced by human immunodeficiency virus type 1NC in uninfected and previously infected chimpanzees. The Journal of Infections Diseases 2001; 75 (3): 1533-1539.

49.         Stott J, Almond N. Assessing animal models of AIDS. Nature Medicine 1995; 1: 295-297.

50.         Shortcomings of AIDS-Related Animal Experimentation. New York, Medical Research Modernization Committee, 1996.

51.         Wyand MS. The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines. AIDS Research and Human Retroviruses 1992; 8: 349-356.

52.         Johnston MI. The role of nonhuman primate models in AIDS vaccine development. Molecular Medicine Today 2000; 6: 267-270.

53.         National Institute of Allergy and Infectious Diseases. Clinical Research on HIV Vaccines May 2005. www.niaid.nih.gov/factsheets/clinrsch.htm.

54.         DeVita Jr. VT, Hellman S, Rosenberg SA. AIDS Etiology, Diagnosis, Treatment, and Prevention, 3rd Edition. Philadelphia, JB Lippincott, 1992.

55.         Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-3'deoxythymidine (BS A509U). Proceedings of the National Academy of Sciences USA 1985; 82: 7096-7100.

56.         Soudeyns H, Yao X-J, Gao Q, et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH 189), a novel heterocyclic nucleoside analog. Antimicrobial Agents and Chemotherapeutics 1991; 35: 1386-1390.

57.         Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990: 248; 358-361.

58.         Giannelli MA. Three blind mice, see how they run: A critique of behavioral research with animals, in Fox MW, Mickley LD (eds). Advances in Animal Welfare Science 1985/86. Washington DC, Humane Society of the United States, 1985, pp 109-164.

59.         Cohen MJ. The irrelevance of animal experimentation in modern psychiatry and psychology, in Cohen MJ, Natelson N (eds) Facing the Challenge. Alexandria VA, Concern for Helping Animals in Israel, 1991, pp 91-107.

60.         Cohen MJ. Animal testing [letter]. Psychiatric News. Nov 20, 1987.

61.         Bannister D. The fallacy of animal experimentation in psychology, in Sperlinger D (ed). Animals in Research. New York, John Wiley & Sons, 1981, pp 307-317.

62.         Bannister D. The myth of physiological psychology. Bulletin of the British Psychological Society 1968; 21: 229-231.

63.         Shapiro K. Animal Models of Human Psychology: Critique of Science, Ethics and Policy. Seattle, Hogrefe & Huber, 1997.

64.         Plous S. Attitudes towards the use of animals in psychological research and education: Results from a national survey of psychologists. American Psychologist 1996; 51: 1167-1180.

65.         Bowlby J. Maternal care and mental health. Geneva, WHO Monograph Series, No. 2, 1952.

66.         Spitz RA, Wolf KM. Anaclitic depression. Psychoanalytic Studies of the Child 1946; 2: 313-342.

67.         Cohen MJ. A critique of the use of maternally deprived monkeys to study alcohol abuse. MRMC Report 1996; 9(1): 1-2.

68.         Cohen MJ. A critique of maternal deprivation monkey experiments at The State University of New York Health Science Center. MRMC Report 1996; 9(4): 1-8.

69.         Scientists reveal significant behavioral impacts of early life stress, the importance of timed therapies to counteract them. OHSU News Release October 24, 2004. www.ohsu.edu/news/2004/102404stress.html.

70.         Kelly JA. Psychological research and the rights of animals: Disagreement with Miller [letter]. American Psychologist 1986; 41: 839-841.

71.         Dole VP. On the relevance of animal models to alcoholism in humans. Alcoholism Clinical and Experimental Research 1986; 10: 361-363.

72.         Lee T. Gene Future. New York, Plenum Pr, 1993, p 177.

73.         Clarke LL, Grubb BR, Gabriel SE, Smithes O, Koller BH, Boucher RC. Defective epithelial transport in a gene-targeted mouse model of cystic fibrosis. Science 1992; 257: 1125-1128.

74.         Zbinden G, Flury-Roversi M. Significance of the LD50 test for the toxicological evaluation of chemical substances. Archives of Toxicology 1981; 47: 77-99.

75.         Fano A. Lethal Laws: Animal Testing, Human Health and Environmental Policy. London, Zed Books, 1997, pp 157-159.

76.         Stephens M. Replacing animal experiments, in Langley G (ed). Animal Experimentation: The Consensus Changes. New York, Chapman and Hall, 1989, pp 144-168.

77.         Clemedson C, McFarlane-Abdulla E, Andersson M, et al. MEIC evaluation of acute systemic toxicity. Alternatives to Laboratory Animals 1996; 24 (Suppl 1): 273-311.

78.         Shrivastava R. In vitro tests in pharmacotoxicology. Alternatives to Laboratory Animals 1997; 25: 339-340.

79.         www.oecd.org/document/55/0,2340,en_2649_34377_2349687_1_1_1_1,00.html.

80.         Sharpe R. The Draize test – motivations for change. Food and Chemical Toxicology 1985; 23: 139-143.

81.         Freeberg FE, Hooker DT, Griffith JF. Correlation of animal eye test data with human experience for household products: An update. Journal of Toxicology – Cutaneous & Ocular Toxicology 1986; 5: 115-123.

82.         Langley G, Fisher G. New Perspectives in Cosmetic Toxicology: Non-animal Tier-Testing Strategies. London, International Fund for Animal Welfare, 1995.

83.         Lave LB, Ennever FK, Rosenkranz HS, Omenn GS. Information value of the rodent bioassay. Nature 1988; 336: 631-633.

84.         Seidle T. Creative Accounting: (Mis)judging the costs and benefits of rodent cancer studies by the UK Home Office May 2006. PETA Europe Limited. www.peta.org.uk/feat/pdf/Creative_Accounting.pdf.

85.         Worth AP, Balls M (eds). Alternative (non-animal) methods for chemical testing: Current status and future prospects. Alternatives to Laboratory Animals 2002; 30 (Suppl 1): 83-93.

86.         http://dtp.nci.nih.gov/branches/btb/ivclsp.html.

87.         Kerkvliet GK. Drug discovery screen adapts to changes. Journal of the National Cancer Institute 1990; 82: 1087-8.

88.         Bailey J, Knight A, Balcombe J. The future of teratology research is in vitro. Biogenic Amines, 2005; 19 (2): 97-145.

89.         www.pcrm.org/resch/meded/index.html.

90.         Fawver AL, Branch CE, Trentham L, Robertson BT, Beckett SD. A comparison of interactive videodisc instruction with live animal laboratories. American Journal of Physiology 1990; 259 (Adv Physiol Educ 4): S11-S14.

91.         Hepner LA. Animals in Education. Albuquerque, NM, Richmond Pub, 1994.

92.         Tan GM, Ti LK, Suresh S, Ho BS, Lee TL. Teaching first-year medical students physiology: Does the human patient simulator allow for more effective teaching? Singapore Medical Journal 2002; 43: 238-42.

93.         Friedrich MJ. Practice makes perfect: Risk-free medical training with patient simulators. Journal of the American Medical Association 2002; 288: 2808-12.

94.         Kaufmann CR. Surgical simulation: A clinical perspective. Military Medicine 2003; 168: 16-20.

95.         Balcombe J. Medical training using simulation: Toward fewer animals and safer patients. Alternatives to Laboratory Animals  2004; 32 (supp 1): 553-60.

96.         Gordon JA, Oriol NE, Cooper JB. Bringing good teaching cases “to life”: A simulator-based medical education service. Academic Medicine 2004; 79: 23-7.

97.         Issenberg SB, McGaghie WC, Petrusa ER, Gordon DL, Scalese RJ. Features and uses of high-fidelity medical simulations that lead to effective learning: A BEME systematic review. Medical Teacher 2005; 27: 10-28.

98.         Groopman J. A model patient: how simulators are changing the way doctors are trained. The New Yorker, May 2, 2005: 48-54.

99.         Patel AD, Gallagher AG, Nicholson WJ, Cates CU. Learning curves and reliability measures for virtual reality simulation in the performance assessment of carotid angiography. Journal of the American College of Cardiology 2006; 47: 1796-1802.

100.     www.facs.org/education/accreditationprogram/index.html.

101.     LaFollette H, Shanks N. Animal models in biomedical research: Some epistemological worries. Public Affairs Quarterly 1992; 7: 113-130.

102.     LaFollette H, Shanks N. Brute Science. New York, Routledge, 1997.

103.     Kaufman SR, Reines BP, Casele H, Lawson L, Lurie J. An evaluation of ten randomly chosen animal models of human diseases. Perspectives on Animal Research 1989; 1 (Suppl): 1-128.

104.     Kaufman SR, Czarnecki T, Haralabatos I, Richardson M. Animal models of degenerative neurological diseases. Perspectives on Medical Research 1991; 3: 9-48.

105.     Smith CD. A critique of brain wound research. Perspectives on Animal Research 1989; 1: 19-24.

106.     Buyukmihci NC. Response to Dr. Blakemore's assertion that work involving nonhuman animals has led to significantly greater understanding and treatment of amblyopia. Perspectives on Animal Research 1989; 1: 57-62.

107.     Cohen MJ, Black DN, Fouts RS, Dobbs FW. A critique of neurology experiments at Northwestern University. Perspectives on Medical Research 1993; 4: 22-28.

108.     Kaufman SR. Animal models of spinal cord injury. Perspectives on Medical Research 1990; 2: 1-12.

109.     Mack JD, Greenberg RA. Review of scoliosis research at the University of Michigan. Perspectives on Medical Research 1990; 2: 33-36.

110.     Committee on Animal Models in Biomedical Research. Aping Science. Medical Research Modernization Committee, New York, 1995.

111.     Barnard ND, Hou S. Inherent stress: The tough life in lab routine. Lab Animal Sept 1988, pp 21-27.

112.     Balcombe JP, Barnard ND, Sandusky C. Laboratory routines cause animal stress. Contemporary Topics 2004; 43: 42-51.

113.     Hewitt HB. The use of animals in experimental cancer research, in Sperlinger D (ed). Animals in Research. New York, John Wiley & Sons, 1981.

114.     Freedman DA, Zeisel H. From mouse to man: The quantitative assessment of cancer risks. Statistical Science 1988; 3: 3-28.

115.     Smith CD. Head injury research at the University of Cincinnati. Perspectives on Animal Research 1989; 1: 9-18.

116.     Ames BN, Gold LS. Too many rodent carcinogens: Mitogenesis increases mutagenesis. Science 1990; 249: 970-971.

117.     Wiebers DO, Adams HP, Whisnant JP. Animal models of stroke: Are they relevant to human disease? Stroke 1990; 21: 1-3.

118.     Habal MB. The influence of lip repair with and without soft-tissue undermining on facial growth in beagles [discussion]. Plastic and Reconstructive Surgery 1988; 82: 756-759.

119.     Fernandes D. Animal experimentation: Necessary or not? Cleft Palate Journal 1989; 26: 258.

120.     Wiebers DO, Adams HP, Whisnant JP. Relevance of animal models to stroke [letter]. Stroke 1990; 21: 1091-1092.

121.     Macleod MR, O’Collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 2004; 35: 1203-8.

122.     Macleod M. What can systematic review and meta-analysis tell us about the experimental data supporting stroke drug development? International Journal of Neuroprotection and Neuroregeneration 2005; 1: 201.

123.     The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine 1995; 333: 1581-7.

124.     Weiss R. Boy’s cancer prompts FDA to halt gene therapy. Washington Post, March 4, 2005, p A02.

125.     Harris G. Gene therapy is facing a crucial hearing. New York Times, March 3, 2005, p A16.

126.     Pollack A. Gene therapy for hemophilia shows some promise. New York Times, Dec 10, 2002, p F2.

127.     Pollack A. Company discontinues trial of hemophilia gene therapy. New York Times, May 28, 2004, p C2.

128.     Sharpe R. Science on Trial. Sheffield, England, Awareness Pub, 1994.

129.     Packer M, Carver JR, Rodeheffer RJ, et al. Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure. New England Journal of Medicine 1991; 325: 1468-1475.

130.     McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine 1995; 333: 1099-1105.

131.     Kolata G. 2 top diet drugs are recalled amid reports of heart defects. New York Times Sept 16, 1997, p A1.

132.     Couzin J. Estrogen Research: The great estrogen conundrum. Science, 2003; 302: 1136-1138.

133.     Topol EJ. Failing the public health – Rofecoxib, Merck, and the FDA. New England Journal of Medicine 2004; 351: 1707-1709.

134.     Graham DJ. Testimony before the U.S. Senate Finance Committee, November 18, 2004.

135.     McCollough AR. Four-year review of sildenafil citrate, Reviews in Urology, 2002; 4 (suppl 3): S26-S38.

136.     More Viagra, blindness questions. CBS News, June 27, 2005. www.cbsnews.com/stories/2005/06/27/eveningnews/main704562.shtml?CMP=ILC-SearchStories.

137.     Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. Journal of the American Medical Association 1998; 279: 1200-1205.

138.     Editorial. Drugs tests on trial. Nature 2006; 440: 970.

139.     Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science 1990; 249: 1007-1011.

140.     Soffritti M, Belpoggi F, Esposti DD, Lambertini L. Aspartame induces lymphomas and leukaemias in rats. European Journal of Oncology 2005; 10: 107-16.

141.     Lim U et al. Prospective study of aspartame-containing beverages and risk of hematopoietic and brain cancers. 97th AACR Annual Meeting, abstract #4010, April 4, 2006.

142.     Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD. Kappa-opioids produce significantly greater analgesia in women than in men. Nature Medicine 1996; 2: 1184-1185.

143.     Berardesca E, Maibach IH. Racial differences in sodium lauryl sulphate induced cutaneous irritation: Black and White. Contact Dermatitis 1988; 18: 65-70.

144.     Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proceedings of the National Academy of Sciences 2005; 102: 10604-9.

145.     www.fda.gov/oc/speeches/2004/phrma0403.html.

146.     Innovation or stagnation: Challenge and opportunity on the critical path to new medical products. U.S. Food and Drug Administration Report, March 2004, p. 8. www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf.

147.     Harding A. More compounds failing Phase I. FDA chief warns that high drug attrition rate is pushing up the cost of drug development. The Scientist Aug. 6, 2004.

148.     U.S. General Accounting Office. FDA Drug Review: Postapproval Risks 1976-1985. Publication GAO/PEMD-90-15, Washington, D.C., 1990.

149.     Barber B. The ethics of experimentation with human subjects. Scientific American 1976; 234(2): 25-31.

150.     Eilperin J. EPA using data from chemical tests on humans. Washington Post, June 17, 2005, p A03.

151.     Cole LA. The Eleventh Plague: The Politics of Biological and Chemical Warfare. New York, W.H. Freeman & Company, 1996.

152.     Kiernan V. Radiation doctors abused trust in the name of science. New Scientist Oct 14, 1995, p 8.

153.     Annas GJ. Baby Fae: The "anything goes" school of human experimentation. Hastings Center Report 1985; 15(1): 15-17.

154.     Lifton RJ. The Nazi Doctors. New York, Basic Books, 1986.

155.     Preston R. The Hot Zone. New York, Random House, 1994.

156.     Cohen MJ. Ebola Alice? Texas Republic 1996; 3(2): 27-30.

157.     McKenna MAJ. Monkey virus kills Yerkes researcher. Atlanta Journal-Constitution Dec 12, 1997.

158.     Pennisi E. Monkey virus DNA found in rare human cancers. Science 1997; 275: 748-749.

159.     Baboon cells fail to combat AIDS. Nature 1996; 379: 577.

160.     Hooper E. The River: A Journey to the Source of HIV and AIDS. Boston, Little, Brown & Co, 1999.

161.     Reinhardt V, Roberts A. The African polio vaccine-acquired immune deficiency syndrome connection. Medical Hypotheses 1997; 48: 367-374.

162.     Horowitz LG. Emerging Viruses: AIDS and Ebola. Rockport, Mass, Tetrahedron, 1996.

163.     Allan JS. Xenotransplantation at a crossroads: Prevention versus progress. Nature Medicine 1996; 2: 18-21.

164.     Fano A, Cohen MJ, Cramer M, Greek R, Kaufman SR. Of Pigs, Primates and Plagues: A Layperson's Guide to the Problems with Animal-to-Human Organ Transplants. New York, Medical Research Modernization Committee, 1997.

165.     LeTissier P, Stoye JP, Takeuchi Y, Patience C, Weiss RA. Two sets of human-tropic pig retrovirus. Nature 1987; 389: 681-682.

166.     Kimbrell A. The Human Body Shop. San Francisco, HarperCollins, 1994, pp 183-187.

167.     Rhodes R. Deadly Feasts. New York, Simon & Schuster, 1997.

168.     Epstein SS. Unlabeled milk from cows treated with biosynthetic growth hormones: A case of regulatory abdication. International Journal of Health Services 1996; 26: 173-185.

169.     Epstein SS. A needless new risk of breast cancer. Los Angeles Times, March 20, 1994.

170.     Challcombe DN, Wheeler EE. Safety of milk from cows treated with bovine somatotropin. The Lancet 1994; 344: 815-816.

171.     Cummins R. An international boycott of genetically engineered foods. Pure Food Campaign, Washington, DC, March 4, 1997.

172.     Leonard RE. Codex at the crossroads: Conflict on trade health. Nutrition Week 1995; 25: 4-5.

173.     Heimlich HJ, Patrick EA. The Heimlich maneuver: Best technique for saving any choking victim's life. Postgraduate Medicine 1990; 87: 68-79.

174.     Cohen MJ, Young C. "Alcoholic" Rats and Other Alcohol Research Using Animals. New York, National Research Information Center, 1989.

175.     Sitaram N, Gershon S. Animal models to clinical testing – promises and pitfalls. Progress in Neuropsychopharmacology, Biology and Psychiatry 1983; 7: 227-228.

176.     Davis JM. Antipsychotic drugs, in Kaplan HI, Sadock BJ (eds). Comprehensive Textbook of Psychiatry, Fourth Ed. Baltimore, William and Wilkins, 1985.

177.     Unal B et al. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. British Medical Journal 2005; 331: 614.

178.     Doll R et al. Mortality in relation to smoking: 50 years' observations on male British doctors. British Medical Journal 2004; 328: 1519.

179.     Lower GM. Human carcinogenesis: A disciplinary perspective. Medical Hypotheses 1990; 33: 1-6.

180.     Ornish D, for the Multicenter Lifestyle Demonstration Project Research Group. Avoiding revascularization with lifestyle changes: The multicenter lifestyle demonstration project. American Journal of Cardiology 1998; 82: 72T-76T.

181.     Esselstyn Jr. CB. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease. American Journal of Cardiology 1999; 84: 339-341.

182.     Heimlich HJ. Advantages and safety of clinical research, in Cohen M, Natelson N (eds). Facing the Challenge. Alexandria VA, Concern for Helping Animals in Israel, 1990, pp 123-135.

183.     Pechura CM, Martin JB (eds). Mapping the Brain and Its Functions. Washington DC, National Academy Press, 1991.

184.     Savoy RL. History and future directions of human brain mapping and functional neuroimaging. Acta Psychologica 2001; 107: 9-42.

185.     Taylor-Robinson SD. Applications of magnetic resonance spectroscopy to chronic liver disease. Clinical Medicine 2001; 1: 54-60.

186.     Schmermund A, Baumgart D, Erbel R. Coronary calcification by electron beam tomography: comparison with coronary risk factors and angiography. Journal of Cardiovascular Risk 2000; 7: 99-106.

187.     Hill RB, Anderson RE. The Autopsy: Medical Practice and Public Policy. Boston, Butterworth, 1988.

188.     Kaufman SR. Autopsy: A crucial component of human clinical investigation. Archives of Pathology and Laboratory Medicine 1996; 120: 767-770.

189.     Opie EL. Disease of the Pancreas. Philadelphia, JB Lippincott, 1910.

190.     Barron M. The relation of the islets of Langerhans to diabetes with special reference to cases of pancreatic lithiasis. Surgery, Gynecology and Obstetrics 1920; 31: 437-448.

191.     Ahnen DJ. Are animal models of colon cancer relevant to human disease? Digestive Diseases & Sciences 1985; 30 (12 Suppl): 103S-106S.

192.     Pories SE, Ramchurren N, Summerhayes I, Steele G. Animal models for colon carcinogenesis. Archives of Surgery 1993; 128: 647-653.

193.     Human Pharmacological Services: In Vitro Pharmacology Screening in Human Tissue. Biopta, Glasgow, UK. www.biopta.com/upload/file/bioassays/Biopta%20In%20Vitro%20Pharmacology%20Screening.pdf.

194.     Lasagna L (ed). Postmarketing Surveillance of Multisource Drugs. Boston, Center for the Study of Drug Development, 1986.

195.     van Boxtel CJ, Wang G. Some observations on pharmacoepidemiology in Europe. Netherlands Journal of Medicine 1997; 51: 205-212.

196.     Pearson OH, Eliel LP, Rawson RW, et al. ACTH- and cortisone-induced regression of lymphoid tumors in man. Cancer 1949; 2: 943-945.

197.     Boesen E. Cytotoxic Drugs in the Treatment of Cancer. London, Edward Arnold, 1969, p 24.

198.     Coley WB. A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysipelas. The Post-Graduate 1893; 8: 278-286.

199.     Caldwell A. Origins of Psychopharmacology: From CPZ to LSD. Springfield, Charles C Thomas, 1970.

200.     Lehmann HE, Kline NS. Clinical discoveries with antidepressant drugs, in Parnham MJ, Bruinvels J (eds). Discoveries in Pharmacology, Volume 1. New York, Elsevier, 1983, pp 209-221.

201.     Sulser F, Mishra R. The discovery of tricyclic antidepressants and their mode of action, in Parnham MJ, Bruinvels J (eds). Discoveries in Pharmacology, Volume 1. New York, Elsevier, 1983, pp 233-247.

202.     Stevens C. Statement before the House Subcommittee on Labor, Health and Human Services, April 30, 1987.

203.     Pihl A. UICC Study Group on chemosensitivity testing of human tumors. Problems – applications – future prospects. International Journal of Cancer 1986; 37: 1-5.

204.     Gura T. Systems for identifying new drugs are often faulty. Science 1997; 278: 1041-1042.

205.     Anon. Drug discovery screen adapts to change. Journal of the National Cancer Institute 1990; 82: 1087.

206.     Waldren C, Correll L, Sognier MA, Puck TT. Measurement of low levels of x-ray mutagenesis in relation to human disease. Proceedings of the National Academy of Sciences USA 1986; 83: 4839-4843.

207.     www.biopta.com, www.asterand.com.

208.     Hayflick L. The choice of the cell substrate for human virus vaccine production. Laboratory Practice 1970; 19: 58-62.

209.     Beale AJ. Use of tissue cultures for testing vaccines. Journal of the Royal Society of Medicine 1978; 71: 681-686.

210.     Hayflick L. Human virus vaccines: Why monkey cells? Science 1972; 176: 183-184.

211.     Hendriksen CFM. Laboratory Animals in Vaccine Production and Control: Replacement, Reduction and Refinement. Boston, Kluwer Academic Pub, 1988.

212.     Metz B, Hendricksen CF, Jiskoot W, Kersten GF. Reduction of animal use in human vaccine quality control: opportunities and problems. Vaccine 2002; 20: 2411-30.

213.     www.hurelcorp.com.

214.     www.entelos.com, www.physiome.org.

215.     Chu WL. Xceleron leads EU microdose programme. Drugresearcher.com Jan. 31, 2006. www.drugresearcher.com/news/ng.asp?id=65500.

216.     Mucke, HAM. Microdosing in translational medicine: Pros and cons. A CHA Advances Report May 2006, Cambridge Healthtech Associates. www.advancesreports.com/ExecSum/Microdosing%20Executive%20Summary_MG.pdf.

217.     Bazell RJ. Smoking dogs: Tobacco institute tries to discount cancer studies. Science 1970; 170: 515.

218.     Auerbach O, Hammond EC, Kirmian D, Garfinkel L. Effects of cigarette smoking on dogs II. Pulmonary neoplasms. Archives of Environmental Health 1970; 21: 754-768.

219.     Gluck JP, Kubacki SR. Animals in biomedical research: The undermining effect of the rhetoric of the besieged. Ethics and Behavior 1991; 2: 157-173.

220.     Weibers DO, Leaning J, White RG. Animal protection and medical science. The Lancet 1994; 343: 902-904.

221.     Kaufman SR. Animal protection and medical science [letter]. The Lancet 1994; 343: 1574.

222.     Dunayer J. Censored: Faculty who oppose vivisection. Z Magazine, April 1993, pp. 57-60.

223.     Arluke A. The ethical socialization of animal researchers. Lab Animal June 1994, pp 30-35.

224.     Moore EJ. Animal Experiments [letter]. The Lancet 1986; 1 (8487): 975.

225.     Phillips M. Savages, drunks and lab animals: The researcher's perception of pain. Society and Animals 1993; 1: 61-81.

226.     Howell DA. Antivivisection [letter]. British Medical Journal  1983; 286 (6381): 1894.

227.     Rowan AN. Is justification of animal research necessary? [letter]. Journal of the American Medical Association 1993; 269: 1113-1114.

228.     Buyukmihci NC. Consistency in treatment and moral concern. Journal of the American Veterinary Medical Association 1995; 206: 477-480.

229.     Archibald K. No need for monkeys [letter]. New Scientist  July 1, 2006, p 26.

230.     Masson JM, McCarthy S. When Elephants Weep: The Emotional Lives of Animals. New York, Delacorte Press, 1995.

231.     Griffin DR. Animal Minds. Chicago, University of Chicago Press, 1992.

232.     Bekoff M. The Smile of a Dolphin. New York, Discovery Books, 2000.

233.     Langford DJ et al. Social modulation of pain as evidence for empathy in mice. Science 2006; 312 (5782): 1967-1970.

234.     Fouts RS. Next of Kin. New York, William Morrow, 1997.

235.     Patterson F, Linden E. The Education of Koko. New York, Rinehart & Winston, 1991.

236.     AMA White Paper. Use of Animals in Biomedical Research: The Challenge and Response. American Medical Association, 1988.

237.     U.S. Department of Agriculture. 2002 Farm Bill Amendment Section on Rats, Mice, and Birds. www.aphis.usda.gov/ac/farmbill2002.html.

238.     www.sky.com/skynews/polls/displayresults/1,,91153-1003444-2,00.html.

 

 

 

Return to main menu

Table of Contents

End

Home  Info  Join